News

MyChesCo on MSN2d
Aclaris Therapeutics Secures FDA Clearance for ATI-052 Clinical Trial
WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced that the U.S. Food and Drug Administration (FDA) has ...
Medscape20d
The Use of Newer Antiepileptic Drugs in Patients With Renal Failure
Overall, the same concept as in HD applies ... used in the hemodynamically unstable acutely ill patient. The drug clearance will differ when compared with hemodialysis as there is continuous ...
Business Insider3d
Aclaris Therapeutics’ IND for ATI-052 candidate granted FDA clearance
Aclaris Therapeutics (ACRS) announced that the FDA has cleared its Investigational New Drug – IND – application for a Phase ... multiple ascending doses of ATI-052 followed by a proof-of-concept ...
Seeking Alpha3d
Aclaris Therapeutics Secures U.S. Food and Drug Administration IND Clearance for ATI-052, Enabling Advancement of its Novel Bispecific Anti-TSLP/IL-4R Investigational Antibody
Developing bispecific antibodies for immuno-inflammatory disorders is of significant interest to Aclaris, and the clearance of the ... 052 followed by a proof-of-concept portion in an undisclosed ...
Pharmabiz29d
SineuGene Therapeutics receives US FDA’s investigational new drug application clearance for SNUG01 to treat amyotrophic lateral sclerosis
has cleared its Investigational New Drug (IND) application for SNUG01 - a first-in-class TRIM72 (Tripartite Motif Protein 72) - targeted gene therapy candidate for amyotrophic lateral sclerosis (ALS).